Subjects With T2D or at Risk of T2D Cohort Follow-up

NCT05567692 | Active Not Recruiting

• 1 other identifier: 2022-A01538-35
• Study Type: observational
• Target: 837
• Locations: 1 country
• Sites: 1

Brief Summary

The main objective of this study is to prospectively follow the subjects included in "Descendance" cohort and to describe the occurrence of type 2 diabetes in non-diabetic subjects, which will allow us to iteratively update the "Descendance" Type 2 Diabetes risk prediction model.

Conditions

Diabetes Mellitus, Type 2

Keywords

Type 2 diabetes ; Risk Prediction ; Prevention

Outcome Measures

Primary Outcomes (1)

• Type 2 diabetes incidence in Descendance population

  Presence of type 2 diabetes mellitus, on basis of self-reported (physician diagnosis) or diagnosed by OGTT and HbA1c

  9years

Secondary Outcomes (2)

• Provide estimates of prevalence of diabetes and prediabetes in Descendance population

  at baseline, 3-, 6- and 9-years follow-up

• Study of interactions between risk factors on type 2 diabetes incidence

  at baseline, 3-, 6- and 9-years follow-up

Study Arms (2)

T2D group

subjects with type 2 diabetes

Other: Questionnaire

Non-T2D group

healthy subjects

Diagnostic Test: OGTT; Other: HbA1c; Other: Questionnaire

Interventions

OGTT DIAGNOSTIC_TEST

Oral Glucose Tolerance Test

Non-T2D group

HbA1c OTHER

HbA1c measurement

Non-T2D group

Questionnaire OTHER

Follow-up questionnaire

Non-T2D group; T2D group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All subjects included in the DESCENDANCE clinical trial (Id: NCT01727349) between 20011 and 2020, will be re-invited to participate in the Descendance cohort follow-up.

You may qualify if:

• Subjects have participated in the Descendance study
• Subjets who sign informed consent to participate in the study

You may not qualify if:

• Subjects not enrolled in Descendance study
• Subjects refusing to participate
• Pregnant or breastfeeding
• Subjects in emergency situations, under legal protection or unable to provide informed -consent
• Subjects lost to follow-up or died

Sponsors & Collaborators

• Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète: lead
• Institut Pasteur de Lille: collaborator

Study Sites (1)

Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète

Évry, 91058, France

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Interventions

Glucose Tolerance Test; Surveys and Questionnaires

Condition Hierarchy (Ancestors)

Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Intervention Hierarchy (Ancestors)

Blood Chemical Analysis; Clinical Chemistry Tests; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Diagnostic Techniques, Endocrine; Investigative Techniques; Data Collection; Epidemiologic Methods; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health

Study Officials

• Guillaume CHARPENTIER, Dr

  Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 22, 2022
• First Posted: October 5, 2022
• Study Start: February 10, 2023
• Primary Completion (Estimated): October 1, 2032
• Study Completion (Estimated): October 1, 2032
• Last Updated: April 15, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)